Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate
Abstract Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teripa...
Gespeichert in:
| Veröffentlicht in: | Bone (New York, N.Y.) N.Y.), 2010-04, Vol.46 (4), p.929-934 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 934 |
|---|---|
| container_issue | 4 |
| container_start_page | 929 |
| container_title | Bone (New York, N.Y.) |
| container_volume | 46 |
| creator | Eastell, Richard Chen, Peiqi Saag, Kenneth G Burshell, Alan L Wong, Mayme Warner, Margaret R Krege, John H |
| description | Abstract Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women ( N = 159) and men ( N = 38) with GIO were randomized to either teriparatide 20 μg/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO. |
| doi_str_mv | 10.1016/j.bone.2009.12.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877570099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S8756328209021231</els_id><sourcerecordid>877570099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-ee8ce1cd638dd12370c5ddc8310855f3808f98c9c04189df8deb6740b7444bf33</originalsourceid><addsrcrecordid>eNqFkU1v1DAURS1URIfCH2CBvOsq4dlOYmdTqVR8SZVYQNdWYr-Apxk7tZ2i_vs6TMuWlaWnc6_kewh5x6BmwLoP-3oMHmsO0NeM18DZC7JjSoqKy06ckJ2SbVcJrvgpeZ3SHgBEL9krcloiHYBUO5I_lgo6hXgYsgueHoZ4izFR5-lSLuhzon9c_k1_zasJJsTsTHC2ct6uBi0NKWNYQgzJJZojDrkc_wYyRrcMsZRYpCHSYUZvY_CFeENeTsOc8O3Te0ZuPn_6efW1uv7-5dvV5XVlhOpzhagMMmM7oaxlXEgwrbVGCQaqbSehQE29Mr2BhqneTsri2MkGRtk0zTgJcUbOj71LDHcrpqwPLhmc58FjWJNWUrayrNf_l5RCNG0HvCskP5Km_DlFnPQSXVntQTPQmxa915sWvWnRjOuipYTeP9Wv4wHtv8izhwJcHAEsc9w7jNrMzjszzLf4gGkf1ujLUprpVBr1j83sJhb6Us8FE48llKGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733456026</pqid></control><display><type>article</type><title>Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Eastell, Richard ; Chen, Peiqi ; Saag, Kenneth G ; Burshell, Alan L ; Wong, Mayme ; Warner, Margaret R ; Krege, John H</creator><creatorcontrib>Eastell, Richard ; Chen, Peiqi ; Saag, Kenneth G ; Burshell, Alan L ; Wong, Mayme ; Warner, Margaret R ; Krege, John H</creatorcontrib><description>Abstract Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women ( N = 159) and men ( N = 38) with GIO were randomized to either teriparatide 20 μg/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO.</description><identifier>ISSN: 8756-3282</identifier><identifier>EISSN: 1873-2763</identifier><identifier>DOI: 10.1016/j.bone.2009.12.021</identifier><identifier>PMID: 20060078</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Alendronate - therapeutic use ; Biomarkers - blood ; Bone Density - drug effects ; Bone Density - physiology ; Bone Density Conservation Agents - therapeutic use ; Chi-Square Distribution ; Double-Blind Method ; Female ; Glucocorticoids - adverse effects ; Humans ; Male ; Middle Aged ; Orthopedics ; Osteocalcin - blood ; Osteogenesis - drug effects ; Osteogenesis - physiology ; Osteoporosis - chemically induced ; Osteoporosis - drug therapy ; Osteoporosis - metabolism ; Peptide Fragments - blood ; Procollagen - blood ; Teriparatide - therapeutic use ; Treatment Outcome</subject><ispartof>Bone (New York, N.Y.), 2010-04, Vol.46 (4), p.929-934</ispartof><rights>Copyright 2009. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-ee8ce1cd638dd12370c5ddc8310855f3808f98c9c04189df8deb6740b7444bf33</citedby><cites>FETCH-LOGICAL-c389t-ee8ce1cd638dd12370c5ddc8310855f3808f98c9c04189df8deb6740b7444bf33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20060078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eastell, Richard</creatorcontrib><creatorcontrib>Chen, Peiqi</creatorcontrib><creatorcontrib>Saag, Kenneth G</creatorcontrib><creatorcontrib>Burshell, Alan L</creatorcontrib><creatorcontrib>Wong, Mayme</creatorcontrib><creatorcontrib>Warner, Margaret R</creatorcontrib><creatorcontrib>Krege, John H</creatorcontrib><title>Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate</title><title>Bone (New York, N.Y.)</title><addtitle>Bone</addtitle><description>Abstract Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women ( N = 159) and men ( N = 38) with GIO were randomized to either teriparatide 20 μg/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO.</description><subject>Adult</subject><subject>Aged</subject><subject>Alendronate - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - physiology</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Chi-Square Distribution</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Glucocorticoids - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Orthopedics</subject><subject>Osteocalcin - blood</subject><subject>Osteogenesis - drug effects</subject><subject>Osteogenesis - physiology</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - metabolism</subject><subject>Peptide Fragments - blood</subject><subject>Procollagen - blood</subject><subject>Teriparatide - therapeutic use</subject><subject>Treatment Outcome</subject><issn>8756-3282</issn><issn>1873-2763</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAURS1URIfCH2CBvOsq4dlOYmdTqVR8SZVYQNdWYr-Apxk7tZ2i_vs6TMuWlaWnc6_kewh5x6BmwLoP-3oMHmsO0NeM18DZC7JjSoqKy06ckJ2SbVcJrvgpeZ3SHgBEL9krcloiHYBUO5I_lgo6hXgYsgueHoZ4izFR5-lSLuhzon9c_k1_zasJJsTsTHC2ct6uBi0NKWNYQgzJJZojDrkc_wYyRrcMsZRYpCHSYUZvY_CFeENeTsOc8O3Te0ZuPn_6efW1uv7-5dvV5XVlhOpzhagMMmM7oaxlXEgwrbVGCQaqbSehQE29Mr2BhqneTsri2MkGRtk0zTgJcUbOj71LDHcrpqwPLhmc58FjWJNWUrayrNf_l5RCNG0HvCskP5Km_DlFnPQSXVntQTPQmxa915sWvWnRjOuipYTeP9Wv4wHtv8izhwJcHAEsc9w7jNrMzjszzLf4gGkf1ujLUprpVBr1j83sJhb6Us8FE48llKGE</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Eastell, Richard</creator><creator>Chen, Peiqi</creator><creator>Saag, Kenneth G</creator><creator>Burshell, Alan L</creator><creator>Wong, Mayme</creator><creator>Warner, Margaret R</creator><creator>Krege, John H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>20100401</creationdate><title>Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate</title><author>Eastell, Richard ; Chen, Peiqi ; Saag, Kenneth G ; Burshell, Alan L ; Wong, Mayme ; Warner, Margaret R ; Krege, John H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-ee8ce1cd638dd12370c5ddc8310855f3808f98c9c04189df8deb6740b7444bf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alendronate - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - physiology</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Chi-Square Distribution</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Glucocorticoids - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Orthopedics</topic><topic>Osteocalcin - blood</topic><topic>Osteogenesis - drug effects</topic><topic>Osteogenesis - physiology</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - metabolism</topic><topic>Peptide Fragments - blood</topic><topic>Procollagen - blood</topic><topic>Teriparatide - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eastell, Richard</creatorcontrib><creatorcontrib>Chen, Peiqi</creatorcontrib><creatorcontrib>Saag, Kenneth G</creatorcontrib><creatorcontrib>Burshell, Alan L</creatorcontrib><creatorcontrib>Wong, Mayme</creatorcontrib><creatorcontrib>Warner, Margaret R</creatorcontrib><creatorcontrib>Krege, John H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Bone (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eastell, Richard</au><au>Chen, Peiqi</au><au>Saag, Kenneth G</au><au>Burshell, Alan L</au><au>Wong, Mayme</au><au>Warner, Margaret R</au><au>Krege, John H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate</atitle><jtitle>Bone (New York, N.Y.)</jtitle><addtitle>Bone</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>46</volume><issue>4</issue><spage>929</spage><epage>934</epage><pages>929-934</pages><issn>8756-3282</issn><eissn>1873-2763</eissn><abstract>Abstract Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women ( N = 159) and men ( N = 38) with GIO were randomized to either teriparatide 20 μg/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO.</abstract><cop>United States</cop><pmid>20060078</pmid><doi>10.1016/j.bone.2009.12.021</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-3282 |
| ispartof | Bone (New York, N.Y.), 2010-04, Vol.46 (4), p.929-934 |
| issn | 8756-3282 1873-2763 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_877570099 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Alendronate - therapeutic use Biomarkers - blood Bone Density - drug effects Bone Density - physiology Bone Density Conservation Agents - therapeutic use Chi-Square Distribution Double-Blind Method Female Glucocorticoids - adverse effects Humans Male Middle Aged Orthopedics Osteocalcin - blood Osteogenesis - drug effects Osteogenesis - physiology Osteoporosis - chemically induced Osteoporosis - drug therapy Osteoporosis - metabolism Peptide Fragments - blood Procollagen - blood Teriparatide - therapeutic use Treatment Outcome |
| title | Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A18%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20formation%20markers%20in%20patients%20with%20glucocorticoid-induced%20osteoporosis%20treated%20with%20teriparatide%20or%20alendronate&rft.jtitle=Bone%20(New%20York,%20N.Y.)&rft.au=Eastell,%20Richard&rft.date=2010-04-01&rft.volume=46&rft.issue=4&rft.spage=929&rft.epage=934&rft.pages=929-934&rft.issn=8756-3282&rft.eissn=1873-2763&rft_id=info:doi/10.1016/j.bone.2009.12.021&rft_dat=%3Cproquest_cross%3E877570099%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733456026&rft_id=info:pmid/20060078&rft_els_id=1_s2_0_S8756328209021231&rfr_iscdi=true |